Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05967416 · ClinicalTrials.gov registry record · Phase 1
Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma
A Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, sponsored by SIRPant Immunotherapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 3
- Study locations
NCT05967416: Recruiting Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, sponsored by SIRPant Immunotherapeutics.
NCT05967416 is a Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma that is actively recruiting participants, run by SIRPant Immunotherapeutics. The registered enrollment target is 24 participants, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05967416, a Phase 1 study of Refractory Non-Hodgkin Lymphoma and Relapsed Non-Hodgkin Lymphoma, is actively recruiting participants, sponsored by SIRPant Immunotherapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 3
- Study locations
Study Summary
The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims to answer is if SIRPant-M alone or in combination with radiotherapy is safe and well-tolerated.
Primary Outcome
Includes evaluation of frequency and severity of AEs, serious adverse events (SAEs), TEAEs, and adverse events of special interest (AESIs), including injection site reactions and abnormalities in clinical laboratory assessments, vital signs, or physical examination findings. Graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.
Conditions Studied
Interventions
- BIOLOGICAL SIRPant-M
- RADIATION External-beam radiotherapy (XRT)
Study Locations (3)
California
- City of Hope - Duarte
New Jersey
- Hackensack University Medical Center - Hackensack
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-01-17 |
| Est. Completion | 2025-12 |
| Phase | Phase 1 |
What NCT05967416 shows while recruiting
NCT05967416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 95-participant average among 17 other Refractory Non-Hodgkin Lymphoma trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Refractory Non-Hodgkin Lymphoma appearing as the primary indexed condition, and to 2 interventions - of which SIRPant-M is the first listed.
NCT05967416 reports a single indexed study location in California, New Jersey, Texas.
Frequently Asked Questions
What is clinical trial NCT05967416 about?
NCT05967416 is a clinical study titled "Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma". The goal of this study is to test SIRPant-M (RB-1355) , an autologous cell therapy, alone or in combination with focal external-beam radiotherapy in participants with relapsed or refractory non-Hodgkin's lymphoma (NHL). Two dose levels of SIRPant-M are being tested. The main question this study aims...
What is the current status of trial NCT05967416?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2024-01-17. Estimated completion is 2025-12.
What conditions does trial NCT05967416 study?
This clinical trial studies the following conditions: Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT05967416?
The interventions under investigation include: SIRPant-M (BIOLOGICAL), External-beam radiotherapy (XRT) (RADIATION).
Who is sponsoring clinical trial NCT05967416?
This trial is sponsored by SIRPant Immunotherapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05967416 being conducted?
This trial has 3 study locations across California, New Jersey, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Refractory Non-Hodgkin Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05967416's enrollment target sits among peer trials
24 11th of 17 higher than 5 of 17 other Refractory Non-Hodgkin Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Refractory Non-Hodgkin Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
RECRUITING · Phase 1
-
SynKIR-310 for Relapsed/Refractory B-NHL
RECRUITING · Phase 1
-
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
RECRUITING · Phase 1
-
Study of LYL314 in Aggressive Large B-Cell Lymphoma
RECRUITING · Phase 1
-
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
RECRUITING · Phase 1
-
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI